Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 3

REGENERON PHARMACEUTICALS INC

Form 3 June 14, 2007

FORM 3 UNI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

response...

3235-0104

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement REGENERON PHARMACEUTICALS INC [REGN] À McCorkle Douglas S (Month/Day/Year) 06/08/2007 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 777 OLD SAW MILL RIVER (Check all applicable) **ROAD** (Street) 6. Individual or Joint/Group 10% Owner Director _X__ Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting VP, Controller and Asst. Treas Person TARRYTOWN, NYÂ 10591 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Common Stock I By 401(k) Plan 2,732 Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title	Security	Direct (D)	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Incentive Stock Option (right to buy)	(1)	01/05/2011	Common Stock	1,249	\$ 8.5	D	Â
Incentive Stock Option (right to buy)	(1)	12/18/2011	Common Stock	2,238	\$ 8.5	D	Â
Incentive Stock Option (right to buy)	(1)	12/20/2012	Common Stock	1,422	\$ 8.5	D	Â
Incentive Stock Option (right to buy)	(2)	12/15/2014	Common Stock	5,625	\$ 9.49	D	Â
Incentive Stock Option (right to buy)	(1)	12/19/2015	Common Stock	8,000	\$ 11.64	D	Â
Incentive Stock Option (right to buy)	(2)	12/15/2013	Common Stock	4,000	\$ 13	D	Â
Incentive Stock Option (right to buy)	(2)	12/18/2016	Common Stock	11,162	\$ 20.32	D	Â
Non-Qualified Stock Option (right to buy)	(1)	12/18/2011	Common Stock	386	\$ 8.5	D	Â
Non-Qualified Stock Option (right to buy)	(1)	12/20/2012	Common Stock	2,077	\$ 8.5	D	Â
Non-Qualified Stock Option (right to buy)	(2)	12/15/2014	Common Stock	1,875	\$ 9.49	D	Â
Non-Qualified Stock Option (right to buy)	(2)	12/15/2013	Common Stock	4,000	\$ 13	D	Â
Non-Qualified Stock Option (right to buy)	(2)	12/18/2016	Common Stock	8,838	\$ 20.32	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
reporting 6 whot Pulme / Pulme 655	Director	10% Owner	Officer	Other	
McCorkle Douglas S 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	Â	Â	VP, Controller and Asst. Treas	Â	

Signatures

/s/**Douglas S.
McCorkle

**Signature of Reporting
Person

Date

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 3

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option award vests in four equal annual installments, commencing one year after the date of grant.
- (2) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.